Oxybutynin/Gabapentin

奥昔布宁/加巴喷丁

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOxybutynin/Gabapentin

Drug Alias Name加巴喷丁/奥昔布宁Gabapentin+Oxybutynin奥昔布宁+加巴喷丁Gabapentin/OxybutyninOxybutynin+Gabapentin +[7]

ClassificationSmall molecules

Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 2 blockersVoltage-gated N-type calcium channel alpha-1B subunit blockersMuscarinic acetylcholine receptor antagonists

TargetsVoltage-gated N-type calcium channel alpha-1B subunitVoltage-gated calcium channel alpha2/delta subunit 2Muscarinic acetylcholine receptor

Therapy Area/IndicationsUrinary Bladder, Overactive

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Gabapentin Oxybutynin

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesDynogen

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDynogen

Active IndicationsN/A

Inactive IndicationsUrinary Bladder, Overactive

Other Information

ATC CodeN/A